Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Effect of long-term treatment with galantamine on weight of patients with Alzheimer's dementia.

Droogsma E, van Asselt DZ, van Steijn JH, Schuur T, Huinink EJ.

J Nutr Health Aging. 2013;17(5):461-5. doi: 10.1007/s12603-012-0420-6.

PMID:
23636548
2.

Cholinesterase inhibitors for Alzheimer's disease.

Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Review.

3.

Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.

Mucha L, Shaohung S, Cuffel B, McRae T, Mark TL, Del Valle M.

J Manag Care Pharm. 2008 Jun;14(5):451-61.

4.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2002;(3):CD001747. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD001747.

PMID:
12137632
5.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(4):CD001747. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD001747.

PMID:
11687119
6.

Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.

Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, Olivieri F, Marchegiani F, Chiamenti AM, Benussi L, Ghidoni R, Nacmias B, Bagnoli S, Ginestroni A, Scarpino O, Feraco E, Gianni W, Cruciani G, Paganelli R, Di Iorio A, Scognamiglio M, Grimaldi LM, Gabelli C, Sorbi S, Binetti G, Crepaldi G, Franceschi C.

CNS Drugs. 2010 Feb;24(2):163-76. doi: 10.2165/11310960-000000000-00000.

PMID:
20088621
7.

The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.

Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV.

Arch Neurol. 2004 Feb;61(2):252-6.

PMID:
14967774
8.

[Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands].

Wouters CJ, Dautzenberg L, Thissen A, Dautzenberg PL.

Tijdschr Gerontol Geriatr. 2010 Jun;41(3):146-50. Dutch.

PMID:
20593742
9.

Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.

López-Pousa S, Olmo JG, Franch JV, Estrada AT, Cors OS, Nierga IP, Gelada-Batlle E.

Age Ageing. 2006 Jul;35(4):365-71.

10.
11.

Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.

Aronson S, Van Baelen B, Kavanagh S, Schwalen S.

Drugs Aging. 2009;26(3):231-9. doi: 10.2165/00002512-200926030-00004.

PMID:
19358618
12.

Galantamine for Alzheimer's disease and mild cognitive impairment.

Loy C, Schneider L.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001747. Review.

PMID:
16437436
13.

BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.

Chianella C, Gragnaniello D, Maisano Delser P, Visentini MF, Sette E, Tola MR, Barbujani G, Fuselli S.

Eur J Clin Pharmacol. 2011 Nov;67(11):1147-57. doi: 10.1007/s00228-011-1064-x. Epub 2011 Jun 1.

PMID:
21630031
14.

Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.

López-Pousa S, Turon-Estrada A, Garre-Olmo J, Pericot-Nierga I, Lozano-Gallego M, Vilalta-Franch M, Hernández-Ferràndiz M, Morante-Muñoz V, Isern-Vila A, Gelada-Batlle E, Majó-Llopart J.

Dement Geriatr Cogn Disord. 2005;19(4):189-95. Epub 2005 Jan 25.

PMID:
15677866
15.

Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial.

Rockwood K, Fay S, Song X, MacKnight C, Gorman M; Video-Imaging Synthesis of Treating Alzheimer's Disease (VISTA) Investigators.

CMAJ. 2006 Apr 11;174(8):1099-105. Epub 2006 Mar 22.

16.

A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.

Chu LW, Yik PY, Mok W, Chung CP.

Int J Clin Pract. 2007 Mar;61(3):403-10.

PMID:
17313606
18.

Galantamine for Alzheimer's disease.

Loy C, Schneider L.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001747. Review. Update in: Cochrane Database Syst Rev. 2006;(1):CD001747.

PMID:
15495017
19.
20.

A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.

Wattmo C, Paulsson E, Minthon L, Londos E.

Clin Interv Aging. 2013;8:329-39. doi: 10.2147/CIA.S40087. Epub 2013 Mar 20.

Items per page

Supplemental Content

Write to the Help Desk